GET DAILY SIGNALS10x Genomics (TXG) Q3 Earnings: Narrower Loss and Stronger Margins Despite Instrument Revenue Drop
Key Takeaways
- Third quarter revenue reached $150.7 million, up 1.1% year over year and slightly above the roughly $148 million consensus estimate.
- GAAP net loss narrowed to -$0.15 per share, beating the consensus estimate of about -$0.26 per share.
- Gross margin expanded sharply to 75%, up from 67% in the prior-year period, driven by lower inventory write-downs and product mix.
- Management raised full-year 2026 revenue guidance to $625 million–$635 million, up from $610 million–$630 million.
- Total instrument revenue fell 43%, while consumables revenue rose 5%, led by 16% growth in spatial consumables.
- The company now expects to ship roughly 50 Atera instruments by year-end, up from a prior target of about 40.
Earnings Context and Why It Matters
10x Genomics (TXG), a life science technology company focused on single-cell and spatial biology, reported results for the third quarter ended September 30, 2026. This quarter matters because it sits at a pivotal transition for the company: the recently launched Atera spatial platform is beginning to ship, while legacy Chromium, Visium, and Xenium instrument sales are moderating as customers await the new system. Investors are watching whether recurring consumables demand can offset declining instrument revenue and whether a recovering margin profile can bring the company closer to profitability. With a heavy cash balance and a disciplined cost structure, the report offers a key read on how well 10x Genomics is positioning itself for its next growth cycle.
Reported Results
10x Genomics (TXG) posted third quarter revenue of $150.7 million, a 1.1% increase from the prior-year period and modestly above the consensus estimate of roughly $148 million. The company reported a GAAP net loss of $0.15 per share, narrowing from a $0.22 loss a year earlier and beating the consensus estimate of about -$0.26 per share.
Consumables revenue rose 5% to $134.3 million, with spatial consumables up 16% and single-cell consumables roughly flat. Total instrument revenue declined 43%, reflecting a slowdown in Chromium and spatial instrument unit sales ahead of the Atera ramp. Gross margin climbed to 75% from 67%, helped by lower inventory write-downs and a favorable product mix. Total operating expenses fell to $129.0 million from $132.5 million. The company ended the quarter with $576 million in cash, cash equivalents, and marketable securities.
Management also raised its full-year 2026 revenue outlook to a range of $625 million–$635 million, up from $610 million–$630 million, citing stronger-than-anticipated spatial consumables demand and a higher Atera shipment forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Despite the earnings and revenue beats, shares of 10x Genomics (TXG) declined sharply following the release, falling roughly 10% in immediate after-hours trading. The negative reaction suggests investors had priced in stronger growth expectations heading into the report, and the combination of flat overall revenue and a 43% drop in instrument sales tempered enthusiasm. The margin improvement was viewed as encouraging, but much of it stemmed from cost discipline and product mix rather than top-line acceleration. With the stock having rallied substantially into the quarter, the market appeared to be looking for more compelling growth evidence before rewarding the shares further.
Forward Outlook and Key Factors to Monitor
Looking ahead, the near-term narrative centers on the Atera ramp. Management's decision to raise its year-end shipment target from roughly 40 to about 50 instruments signals confidence in production scaling, but execution on manufacturing and customer installation will be the key variable to watch. Atera's success will ultimately be measured by consumables pull-through, not just instrument shipments, given that recurring revenue drives the long-term model.
Investors should also monitor whether spatial consumables momentum can be sustained once Atera is more widely deployed. The strong 16% growth in spatial consumables, even while customers awaited the new platform, suggests healthy underlying demand. Single-cell consumables, by contrast, remain relatively flat, so any reacceleration there would be a meaningful positive signal.
On the cost side, management has indicated that gross margins may step down sequentially in the fourth quarter as Atera instrument shipments increase. Balancing that margin pressure against rising consumables revenue will shape profitability through the rest of the fiscal year. Finally, watch for further guidance updates and any signals on international demand, where results have been uneven across regions. From what I see, the path to sustained growth hinges on execution here.
Using Tickeron AI Tools for Deeper Analysis
In my research on names like this, I frequently rely on Tickeron’s AI Screener to quickly filter opportunities across technical patterns, fundamentals, and industry trends. It provides a structured way to compare peers and surface ideas without manual effort, which helps me stay on top of shifting conditions in the life sciences space. This approach has become a regular part of my process for evaluating earnings reports and positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TXG's Indicator enters downward trend
The Aroon Indicator for TXG entered a downward trend on November 05, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 230 similar instances where the Aroon Indicator formed such a pattern. In 208 of the 230 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for TXG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 23 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXG as a result. In 67 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for TXG turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 36 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
TXG moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TXG crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 210 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
TXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.163) is normal, around the industry mean (4.115). P/E Ratio (-98.407) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry MedicalNursingServices
Advertisement